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Abstract

Islet amylin polypeptide (IAPP) is co-secreted along with insulin in the pancreatic islets of
Langerhans. During type 2 diabetes mellitus, human IAPP (hIAPP) fibrilizes to form amyloid deposits that
are found post-mortem in more than 95% of people with the disease. Rodents do not suffer from type 2
diabetes mellitus as their IAPP (rIAPP) does not undergo self-aggregation. Although the amyloid deposit
is found in those with the disease, the actual cause of the disease is the cytotoxicity of the mechanism
that forms those amyloid deposits. The self-aggregation of IAPP to form amyloid deposits is inhibited by
insulin due to the aromatic π-stacking at the site where IAPP fibrilizes with itself and binds with insulin.
Knowing this, the binding site of both rIAPP and hIAPP (10-19) was synthesized, as was the binding site
of insulin (14-18). The tyrosine in the active site of insulin was replaced with an unnatural amino acid (nmethyl tyrosine) but synthesis failed repeatedly. The ability of hIAPP 10-19 to disrupt membranes was
tested using a dye leakage assay. The fluorescence of the peptide was measured in increasing
concentrations to determine whether their ability to cause cell death is concentration dependent or not.
While the rate of membrane disruption stayed constant, it was determined that overall permeability
increased with concentration of hIAPP 10-19.
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Introduction

1.1 Amino Acids, Proteins, and Peptides
The field of biochemical research is one of the most dynamic in all of science. Over the
past decades the scientific branches of biology and chemistry have become intricately
interwoven so that a hybrid science has been developed. From this new hybrid science,
many diseases, disorders, and conditions have become either partially or completely
curable. However, there is still much work to be done until the complex mechanisms of
living cells and their interactions with each other and exo-chemicals are fully understood.
At the very foundation of biochemistry are amino acids. Amino acids are relatively short
carbon backboned molecules with a carboxyl group, an amino group, and a unique side
chain bonded to the same chiral carbon atom (known as the α–atom). Differences in the
side chains, known as “R-groups,” are what distinguish the amino acids from each other.
Based on their length, structure, charge, and solubility they are the part of the amino acid
that gives it its unique characteristics.
There are twenty amino acids that occur regularly in nature. These can be categorized
according to several different characteristics, but the most common method is to group
them based on the polarity or charge of their R-groups at a pH of 7. Alanine, glycine,
isoleucine, leucine, methionine, proline, and valine are all nonpolar with a saturated carbon
backbone whereas phenylalanine, tryptophan, and tyrosine contain aromatics and are also
hydrophobic. Aspargine, cysteine, glutamine, serine, and threonine are all polar but remain
uncharged at a neutral pH. Arginine, histidine, and lysine have a positive charge, whereas

aspartate and glutamate have a negative charge. All of these amino acids, when produced
by a living organism, are made in the L-conformation with respect to the central α–atom.
When synthetically produced in a laboratory environment, the amino acids are generally
manufactured in a racemic mixture. Unnatural amino acids can be produced by either
slightly altering an existing amino acid or by devising an entirely unique R-group based on
the characteristics the scientist desires.1

Figure 1: The twenty naturally occurring amino acid structures in uncharged, internal forms
with abbreviations.2

2

Amino acids can undergo a condensation reaction in which the C-terminus of one amino
acid reacts with the N-terminus of a second amino acid to form an amide bond and water as
a by-product. This amide bond between amino acids is termed a peptide bond. Formation
of peptide bonds can continue until the amino acid chain becomes several amino acids in
length. This short chain of amino acids is a peptide chain. When this chain is increased even
further in length it is called a polypeptide. A protein is a very long sequence of amino acids
from a few dozen to several thousand in length. The pattern of amino acids in the peptide
chain is very important to their biological function, which can be seen in cases where
changes in less than 1% of the overall sequence results in enormous fluctuations in activity
and function.1 Due to the nature of the sequential condensation reactions, every peptide,
polypeptide, and protein will contain one end with an open carboxyl group (C-terminus) and
one end with an open amino group (N-terminus).1
1.2 Protein Structure
Polypeptides and proteins have very complex and specific structures associated with
them that arise due to the placement of amino acids along the peptide chain. Many of the
characteristics that a protein expresses are due to its conformation. Furthermore, most
proteins have at least one location somewhere along the chain that is arranged in space in
such a way that it interacts with a specific biochemical. This place of interaction is called an
activation site and is designed such that only a very small number of molecules (or synthetic
molecules designed to have key attributes) can attach to it.2

3

Three dimensional structures are broken into four levels: primary, secondary, tertiary,
and quaternary. The primary structure is the actual amino acid sequence of the
polypeptide. The secondary structures are the characteristic helical or pleated segments
that can be formed based on maximized hydrogen bonding of the polypeptide backbone.
The tertiary structures are the bends and folds the molecule adopts to assume a more
compact three dimensional shape. The quaternary structure is the interaction of multiple
tertiary structures, or subunits, in the same molecule to form an overall global
conformation. The primary structure is what is being manipulated to help determine how
certain amino acids along the peptide chain affect both its activity as well as its tertiary
structure. Shorter chained polypeptides only form one tertiary structure and thus it is the
global conformation of the molecule.1, 2
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Figure 2: Illustrations of the levels of peptide structures.3

1.3 Islet Amyloid Polypeptide (IAPP) and Insulin
Islet amyloid polypeptide (IAPP) is a 37 amino acid residue protein secreted by
pancreatic β-cells during the production of insulin. A mammal’s pancreas contains
approximately one to three million β-cells known as the islets of Langerhans.4 IAPP is one of
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a group of peptides that has the ability to undergo a pathway that forms amyloid deposits
and causes cell death. These amyloid deposits of IAPP in the pancreatic islet of Langerhans
are a hallmark of type II diabetes in humans.5, 6 Even though IAPP and insulin are produced
by the same gland, previous studies have shown that the β-cells do not secrete them in the
same ratio, with insulin existing at approximately a 10-to-50-fold higher molar ratio than
IAPP.7 Together, these two hormones are the main regulators of glucose levels in the body.
Insulin causes the cells to transport glucose, thereby lowering the level of glucose in the
blood, whereas IAPP slows the rate at which glucose enters the blood stream. A proper
balance between these two important hormones is necessary in order to ensure that the
blood has the correct amount of glucose in it.8

Figure 3: An overlapping space filling illustration of human islet amyloid polypeptide in
its most likely conformations.9
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Insulin is a polypeptide hormone consisting of 51 amino acids. Much more is known
about insulin than about IAPP due to the vast amount of research that has been done
regarding it. Insulin was the first protein to be fully sequenced, in 1955 by Frederick
Sanger.10 Insulin is synthesized from the proinsulin precursor molecule by the action of
proteolytic enzymes, known as prohormone convertases (PC1 and PC2), as well as the
exoprotease carboxypeptidase E. These modifications of proinsulin remove the center
portion of the molecule, or C-peptide, from the C- and N- terminal ends of the proinsulin.11
The remaining polypeptides (51 amino acids in total), the B- and A- chains, are bound
together by disulfide bonds. The B-chain is the main section of interest in the insulin
molecule due to its interaction with IAPP and will be discussed later.

7

A

B

Figure 4: A space-filling illustration with amino acids shown of the hormone insulin,
clearly showing chains A and B.12

1.4 Amyloid and its Formation
Amyloid is a fibrillar structure resulting from the aggregation and self-assembly of
proteins, peptides, and polypeptides. The formation of amyloid deposits are known to be a
major component of the degenerative processes in diseases such as diabetes, Alzheimer’s,
Prion, and Parkinson’s disease. In type 2 diabetes, amyloid deposits are found post mortem
in approximately 95% of all humans with the disease.13 Every amyloid deposit, regardless of
disease, is primarily composed of one specific protein. In the case of type 2 diabetes, IAPP is
the protein that is the main component of the amyloid deposits.14 This prevalence of
amyloid deposits leads scientists to assume that amyloid formation may contribute to
8

accelerating the degenerative processes of these diseases. Another possibility may be that
the amyloid formation is an inert symptom of the disease itself, but this seems to not be the
case based on previous research done in this area. In all of these diseases, a specific protein
will aggregate into highly ordered beta sheet-rich amyloid fibers in a specific region in the
body.15 However, when in solution IAPP has been documented to exist in every possible
conformation: random coil, α-helix, and β-sheet.16 The conformation that it takes at any
given time seems to be primarily a function of temperature as well as solvent type. New
research has tentatively suggested that the most stable structure for the amyloid fibril is a
beta helix, which is one or more beta sheets wrapped around a hollow core in a helical
manner.16
There is a very large body of research that suggests that a nucleation-dependent
polymerization pathway is the primary method through which amyloid formation by
polypeptides proceeds.17 This pathway consists of two phases: lag and elongation. If the
protein misfolds during the lag phase, formation of oligomeric nuclei occurs, which leads to
the formation of seeds as soluble oligomers.18 Figure 5 demonstrates the probable pathway
of amyloid formation. The nucleus is formed during the lag phase, which subsequently
undergoes aggregation as a result of seeded growth by monomers to form fibrillous amyloid
deposits. These soluble oligomers are much more cytotoxic to pancreatic β-cells than the
mature fibrils.19, 20
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Figure 5: A nucleus of soluble oligomers is formed from misfolding by monomer units of
hIAPP. The nucleus is a soluble oligomer, which is known to be cytotoxic to pancreatic βcells, and can undergo further aggregation to form mature amyloid fibrils.21

1.5 Type 2 Diabetes
Type 2 diabetes, also known as adult onset diabetes mellitus, is a growing epidemic in
modern culture, affecting an approximate 150 million people worldwide. There are several
possible factors for this, with the most likely being a longer lifespan as well as a diet
containing more refined grains and sugars. As mentioned previously, insulin and IAPP are
co-secreted by the pancreas and work together to normalize glucose levels in the
bloodstream. Pancreatic β-cells called islets of Langerhans are directly responsible for the
formation and production of both hormones. In type 1 diabetes mellitus, the autoimmune
disease destroys the β-cells that produce insulin, causing a complete dearth of the hormone
10

in the body. Whereas no known cure exists, injection of insulin directly into the
bloodstream is a simple way of combating the disease.
Before the full onset of type 2 diabetes mellitus, the body’s cells become increasingly
resistant to the effects of insulin regulation. Following insulin resistance, the β-cells that
produce insulin undergo a steady numerical decline, which contributes to decreased
glucose control. These two phases make up the bulk of the disease known as type 2
diabetes. These phases work together in that the progression of one phase causes the
other phase to accelerate. This forms a negative feedback cycle in the body. In order to
cope with the insulin resistance of the body’s cells, the islets are sent biochemical signals
requiring more insulin to be produced. Since insulin and IAPP are co-secreted, this high
insulin production corresponds with an increased IAPP production, which seems to cause
the β-cells to die more quickly than normal. Increased insulin production also causes the
bloodstream to become saturated with insulin, causing further insulin resistance in the
body. The combination of these two factors leads to adult onset diabetes mellitus. 22

1.6 IAPP Inhibition by Insulin
In vivo, IAPP does not spontaneously form fibrils at the typical concentrations of 800 µM
that exist in secretory granules. However, in vitro, wild type IAPP very rapidly forms fibrils at
concentrations as low as 5 µM at conditions that mimic the cellular environment. Knowing
that, it has then been determined that what it is in vivo that prevents the IAPP from forming
fibrils is actually the insulin that is co-secreted along with it. It has also been shown using a
histological stain, Congo red, that insulin actually inhibits the fibril formation of IAPP during
11

the lag phase of fibrillization by forming an insulin-IAPP complex. Within the secretory
granule, in which insulin has a 10-to-50-fold molar excess over IAPP, calculations show that
kinetic inhibition can be maintained for several months even though the lifetime of a
granule is merely hours. The inhibition readily occurs at even substoichiometric levels of
insulin when compared to IAPP. This is thought to ensure that upon secretion from the
pancreas, where dilution occurs, only a very small quantity of insulin is required to inhibit
fibril formation of IAPP. Upon secretion, the IAPP-insulin complex inside the granule
dissociates due to dilution beyond the association-constant concentration. As stated
previously, secretion of insulin and hIAPP is accelerated in adult onset diabetes mellitus.
This causes the unbound IAPP outside of the granule to have a relatively high concentration,
which theoretically will lead to amyloid deposits. Interestingly, unlike amyloid formation,
inhibition is not dependent on the concentration of IAPP.23
Previous studies have determined that the B-chain of insulin directly inhibits amyloid
formation, whereas the A-chain actually increases the rate at which aggregation occurs.
Also, far-UV circular dichroism showed that IAPP in the presence of the B-chain of insulin
showed a conformation change from random coil to β-sheet, which is the conformation at
which amyloidogenesis occurs and cytotoxicity begins.24 Inside of the B-chain of insulin,
there is a sequence of twelve amino acids (9-20) that has the full inhibition effect:
TQRLANFLVH.7 A reciprocal peptide-array analysis using 28 decamer peptides corresponding
to consecutive overlapping fragments of IAPP has been conducted, and it determined that a
single binding domain of hIAPP 7-19 existed, with 10-19 showing the highest affinity.7 This
binding domain on hIAPP is the exact same domain that binds when hIAPP undergoes
12

aggregation.7, 25 This makes sense as it is simple to picture that insulin is binding to IAPP, and
when insulin is no longer present, the IAPP aggregates with itself using the now open
activation site to form an amyloid deposit.
1.7 Mechanism of IAPP and Insulin Interaction
The main hypothesized mechanism of both insulin-IAPP binding and IAPP aggregation is
based on π-stacking interactions. Aromatic units are already known to play a huge role in
molecular recognition and self-assembly of biomolecules. Attractive nonbonding
interactions between planar aromatic rings are referred to as π-π interactions or π-stacking.
It is furthermore suggested that π-stacking is an entropy-driven process because it releases
bound water molecules. Out of the four possible π-stacking geometries, the parallel
displaced structure is the most common one in proteins and is the probable geometrical
arrangement of IAPP aggregation. The parallel displaced structure would contribute to
energy as well as to order and directionality during amyloid formation.13, 7 Figure 6 shows
how the β-sheet conformation formed during amyloid aggregation is strongly supported by
the π-stacking interaction theorized.
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Figure 6: The self-assembling mechanism due to π-stacking of aromatic amino acids to form
a β-sheet is supported by both theory and evidence. 7

Interestingly, when all the amyloidogenic peptides are compared (i.e., IAPP, Alzheimer’s
β-amyloid, aortic medial amyloid, etc.), they do not share any sequence homology.
However, they all do have short functional fragments with very notable aromatic residues.
Such a frequent occurrence of aromatic amino acids is interesting to note, especially
considering the rarity and importance of aromatic amino acids. Aromatic residues occur
14

very rarely, with all three of them (tryptophan, tyrosine, and phenylalanine) being one of
the six least-commonly occurring residues in all of nature, occurring at 1.32%, 3.25%, and
3.91%, respectively. In addition to being rare, aromatic amino acids are also some of the
most highly conserved residues, with tryptophan holding 1st place and phenylalanine and
tyrosine tied for 3rd (cysteine is the 2nd most conserved residue). Furthermore, when the
aromatic residue is not conserved, it is almost always replaced with another aromatic amino
acid.26
Inside of the active fragments mentioned previously, hIAPP 10-19 and insulin 9-20, are
aromatic residues. It has been determined that a shorter, five-fragment residue (23-27,
FGAIL) in hIAPP forms fibrils. However, when this is truncated to GAIL (removal of F) no
fibrils are formed whatsoever. Analysis suggests that the phenylalanine residue present in
the peptide must play a major role as a structural element of the self-assembly process
because the other four amino acids do not have the physicochemical properties necessary
to direct a process of molecular recognition. In the insulin molecule, tyrosine is in the
middle of the section that inhibits IAPP aggregation the most. Insulin 14-18 of the B-chain
(ALYLV) also composes part of the segment that most strongly inhibits IAPP aggregation.7
The combination of these results, as well as how all other amyloidogenic compounds have
similar profiles, greatly support the theory that aromatic residues direct fiber formation of
both the IAPP-insulin dimer and IAPP aggregation. 27
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1.8 Human and Rodent IAPP Comparisons
As previously stated, humans suffer from adult onset diabetes mellitus, of which hIAPP
is a primary component and target of research. However, rodents do not suffer from this
disease, and it is important to know the research that has been done to understand why
this is so.28 The main differences between the human and rat in this area are in the IAPP
hormone itself, especially in the segment 20-29. Table 1 details the differences.

Table 1. Human and rat IAPP peptide sequences.
Species

Sequences
1

Human
Rat

9

KCNTATCAT
KCNTATCAT

10

19

QRLANFLVHS
QRLANFLVRS

20

29

SNNFGAILSS
SNNLGPVLPP

30

37

TNVGSNTY
TNVGSNTY

Note: The human variant forms amyloid whereas the rat variant
does not. Most of the differences are in the 20-29 section, with
position 18 also different. The differences in homology are bolded.

Studies suggest that the proline substitutions (28-29) in the rIAPP prohibit folding into a
β-conformation and from there into amyloid fibrils.29 Interestingly, the phenylalanine at
position 23 is not conserved, which could lead one to believe that it is important in
aggregation of IAPP. However, as previously stated, the active site of making the IAPPinsulin complex is the phenylalanine at position 15, which is conserved. Cysteines, which are
16

the second most conserved and rare amino acid, occur at positions 2 and 7 and do not
affect the activity of either rIAPP or hIAPP if absent.24, 30 Previous studies have shown that
hIAPP and rIAPP 20-29 can be used as analogs to study the entire molecule and its
activity.30, 31 However these portions would not be as useful when comparing its inhibition
by insulin. Multiple sections of IAPP (1-37, 8-37, and 20-29) have been shown using circular
dichroism to undergo the same conformational change to a beta-sheet core of an amyloid
fibril.32 Therefore it would be of value to see how hIAPP and rIAPP 10-19 compare with each
other.
1.9 Membrane Disruption
During adult onset diabetes mellitus, the quantity of β-cells that produces the IAPP and
insulin begin to decrease slowly as part of the pathway previously discussed. This pathway
initially causes the total amount of insulin in the bloodstream to decrease, which causes a
negative feedback cycle, forcing the remaining β-cells to produce even more IAPP and
insulin. The general mechanism through which the β-cells are destroyed is through the
effect that non-bonded hIAPP molecules have on membrane permeability. There are several
suggested specific mechanisms through which IAPP can disrupt membranes, and the
method through which the membrane is disrupted has been shown to depend on
environmental conditions. At low concentrations, the peptides are monomers on the
surface, but as the concentration increases, the peptides begin to self-assemble.33 When
the concentration increases even further, there are three possible mechanisms of
membrane disruption: barrel-stave, detergent-like, and toroidal-wormhole. The barrel-
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stave model has the peptides aggregating to form transmembrane pores. The detergent
model works by the peptides working in the manner that detergents work, pulling apart the
membrane. Finally, the toroidal-wormhole has a mechanism that works by both the lipids
and peptides lining inside a pore, which destabilizes the membrane through curvature
strain.34, 35 Membrane permeability disappears when fibrillization is complete.32 Figure 7
displays a graphical representation of how the peptide affects the membrane of the β-cells.
Overall, there is much debate going on as to the actual mechanism used and most evidence
seems to indicate that all of them occur to some extent. Furthermore, it has been observed
that both the rat and human IAPP cause the membrane to permeabilize, although the rIAPP
is needed in much higher concentrations than the human variant.36
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Figure 7: The six states of peptides in membrane disruption. A – Unstructured peptides in
solution. B – Peptide as a monomer. C – Self assembled peptide on surface. D – Barrel-stave
model. E – Toroidal wormhole model. F – Detergent model.37

1.10 Peptide Synthesis
Peptide synthesis using the solid phase techniques is by far the most common method
of synthesizing peptides currently. This method allows the chemist to easily control the
peptide sequence as well as add any unnatural or D-amino acids if desired. The main
process behind solid phase peptide synthesis is one of repeated coupling and deprotection
19

of amino acids by various solvents. The resin is placed in the reaction vessel and
subsequently deprotected. After deprotection of the resin, the C-terminal amino acid of the
peptide is added, and then that amino acid’s N-terminal α-amine is deprotected, awaiting
the next amino acid to be added to it. Following this pattern, the peptide is synthesized with
the N-terminus being capped with acetic anhydride. This method requires that extremely
high yield be met at every step due to the many steps of the process. If done properly,
overall yields have been reported upwards of 90%.
There are two forms of solid phase peptide synthesis: Fmoc and tBoc. Those are the two
types of protective groups on the end of each of the amino acids. Boc, tertbutyloxycarbonyl, was the method originally pioneered. It has fallen out of favor recently
due the requirement of incubation in hydrofluoric acid to remove the protective group.
Fmoc, fluorenyl-methoxy-carbonyl, is currently the most used method of SPPS. To remove
an Fmoc protective group, 20% piperidine in DMF is usually used, while removal of side
chain protecting groups and cleavage of the peptide and resin requires incubation in
trifluoroacetic acid (TFA). Deprotection of the Fmoc group takes longer than Boc, because
the anionic nitrogen produced as the end product is not highly favorable although it is
thermodynamically driven due to the evolution of carbon dioxide. Some more complex
reactions are more suited to using Boc than Fmoc, especially when unnatural amino acids
that are base-sensitive are being introduced.

20

1.11 Dye-Leakage Assay
In order to test the effects of IAPP on membranes, a dye-leakage assay was developed,
specifically designed to test how well IAPP disrupts membranes. The assay used was
adapted from a similar assay at the University of Michigan for the chemicals, peptides, and
instruments currently available at Eastern Michigan University. Lipid vesicles were created
and filled with carboxyfluorescein, which upon disruption of the membrane would leak into
the surrounding buffer. Carboxyfluorescein is a highly fluorescent molecule, which allows its
concentration to be measured by a constant scanning spectrofluorometer. This
concentration then gives an indication as to the degree to which the membrane is
permeabilized by the IAPP.

21

Research Goals and Objectives
Recently, there has been a plethora of research into both types of diabetes as well as
amyloidogenic diseases in general. This research has been driven by the high proportion of
the population that has these diseases. However, the mechanism through which they
operate is still not completely understood. Amyloid deposits have been found post mortem
in over 95% of patients with type 2 diabetes mellitus. Knowing this, researchers have
focused on determining the mechanism through which those deposits occur. Now having a
general knowledge of this pathway, it has been determined that the end product, the
amyloid deposit itself, it not cytotoxic or a cause of the disease. However, as the research
has continued, it has been determined that oligomeric species of hIAPP are actually the
culprits that cause the death of pancreatic β-cells in the islets of Langerhans. This
comparatively recent development has not been fully researched and is currently the target
of scientists worldwide.
One of the recent directions of new research is to determine in what environment IAPP
does not undergo aggregation and attempt to determine the reason behind this. This
direction of study has led researchers to discover that insulin is a natural inhibitor of IAPP
and recently led to the proposed mechanism of π-stacking as a method of directing an
insulin-IAPP complex as well as IAPP aggregation. From this, the shortest fragments of
peptide that exhibit the traits of the entire hormone, for both IAPP and insulin, have been
studied. Starting with these minimal sequences, the first objective of this research is to
replace the phenylalanine in a short insulin analog with an unnatural amino acid that
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likewise contains an aromatic ring and see how it affects inhibition of IAPP. If successful, this
could eventually lead to a line of drugs that could site-specifically bind to IAPP and
successfully inhibit it from aggregating to form oligomers that are cytotoxic to pancreatic βcells. This requires the synthesis of both the natural penta-peptide segment in insulin,
referred to as LKH-1, as well as the peptide segment with the unnatural amino acid
replacing phenylalanine, referred to as LKH-2.
The second direction of the research has been to compare the IAPP of humans to the
IAPP of a species that does not suffer from adult onset diabetes mellitus. hIAPP and rIAPP
are very similar with very few amino acids that are not conserved between the two. Studies
have been done that compare the two hormones in many different areas, especially known
active segments with specific differences. A predecessor to my research had conducted
extensive comparison studies between segments 20-29 of both the human and rat variants
because that is where the vast majority of the differences lie.33 However, amino acid 18 is
different, and no comparative studies have been done with hIAPP and rIAPP 10-19. Since
that particular amino acid is very near the active site of IAPP’s interaction with insulin
(phenylalanine at position 15), it is of particular interest to discover if that change affects
the ability of the peptide to disrupt the membrane of the β-cells. Synthesis of hIAPP and
rIAPP 10-19 are therefore proposed to further undergo assays to compare their differences.
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Experimental Procedures
3.1 Peptide Synthesis
SPPS requires the amino acid sequence to be arranged in a series of vials. Each vial
contains 0.4 mmol of the desired amino acid along with 0.4 mmol of a coupling agent, Obenzotriazole-N,N,N’,N’-tetramethyluronium hexafluorophosphate (HBTU). The amino acid
vials were arranged in order from C-terminus to N-terminus on the synthesizer, with a vial
of 2.0 mL of acetic anhydride placed after the N-terminus for acetylation. The reaction
vessel contained 0.1 mmol of 4-methylbenzhydrylamine hydrochloride salt (MBHA) resin.
The PS3 peptide synthesizer was run, singly coupling the amino acids. The synthesis was
completed using standard Fmoc methods and resulted in an amidated C-terminus from the
resin, and an acetylated N-terminus. The main solvent was N,N-dimethylformamide (DMF),
a 20% piperidine solution in DMF (v/v) was used for deprotection, and 0.4 M N,Ndiisopropylethylamine in DMF was the coupling activator. During the research project all
amino acids were purchased from Midwest Biotech Inc. or Protein Technologies Inc., while
the other chemicals used were bought from Fisher Scientific and were, at a minimum, ACS
grade. Table 2 lists the sequences synthesized.
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Table 2. The four peptides that were synthesized.
Name
LKH-2
LKH-1
hIAPP 10-19
rIAPP 10-19

Sequence
AL-(N-Methyl-Tyrosine)-LV
ALYLV
QRLANFLVHS
QRLANFLVRS

Note: LKH-2 was not synthesized successfully for reasons
to be discussed later. The rest were all successfully
synthesized, although with varying percent yields.
3.2 Peptide Cleavage
After the synthesis, the peptide was bound to the resin inside of the reaction vessel. The
peptide-bound resin was transferred with DMF to a coarse fritted glass funnel and rinsed
with methylene chloride, then dried for thirty minutes under vacuum. In a 50 mL beaker, a
solution that would cleave the peptide from the resin was prepared and chilled; the solution
contained 0.5 mL anisole, 0.5 mL water, 1 crystal of phenol, and 10 mL TFA. The dried
peptide-bound resin was added to the cleavage solution and stirred at room temperature
for two hours, which caused the peptide to separate from the resin.
After being cleaved from the resin, the peptide went into solution while the resin
remained a solid. The solution was filtered in a coarse fritted glass funnel to remove the
resin, and the filtrate was collected in the sidearm flask, washing with TFA to ensure that all
the peptide was collected. To the remaining filtrate approximately 60 mL of cold diethyl
ether was slowly added while stirring, which caused the synthesized peptide to precipitate
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out of solution. This solid was then filtered in a fine fritted glass funnel and allowed to dry
under vacuum for approximately 30 minutes. The peptide was transferred to a
lyophilization flask, dissolved in a 70% acetonitrile/H2O solution with an equal amount of
distilled H2O added, and frozen. After freezing, it was placed on a lyophilizer overnight to
remove all liquid, leaving behind only the solid synthesized peptide.
3.3 Peptide Purification and Analysis
After lyophilization, the impure peptide was transferred to a weighing vial and weighed
on an analytical balance. The peptide was dissolved in a minimum amount of DMF and
injected onto a purification column for preparative separation using reverse phase(RP)-high
performance liquid chromatography (HPLC). The absorbance selected for monitoring
depends upon the peptide being analyzed. The IAPP peptides synthesized contained
phenylalanine, which has a characteristic absorbance at 254 nm. The insulin peptides
contained tyrosine, which absorbs at 280 nm. Solvent A was 0.1% TFA in water, while
solvent B was 0.1% TFA in acetonitrile (ACN). The column was equilibrated by running the
pumps for 20 minutes at 10 mL/min with the solvents at 90% A / 10% B, and then the
peptide was injected. The gradient used increased solvent B until it became 50% over two
hours. Based on maximum peak absorbance, the peptides were manually separated and
collected in numbered test tubes. The largest peak was almost always the desired peptide.
The test tubes that were suspected of containing the desired peptide were collected,
combined, frozen, and lyophilized overnight.
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Following purification, the peptide was subsequently run on an analytical column using
RP-HPLC to ensure the peptide was pure with no contaminants that were unnoticeable
using the preparative column. The solvents and absorbances were the same as the
preparative separation run completed previously. The pumps were run at 1 mL/min with
the solvent at 100% B. A gradient then equilibrated the column by changing the solvent to
90% A / 10% B over 10 minutes. A tiny remnant of purified peptide was dissolved in a few
drops of DMF and injected into the HPLC. A second gradient brought the solvent
composition up to 30% A / 70% B over 30 minutes. A solvent peak appeared almost
immediately (approximately 1-2 minutes), and then each peptide in the solution gave a
single peak, which would signify the peptide was pure. If there were multiple peaks or
shoulders, the previous separation steps needed to be repeated. The pure peptide then was
weighed, labeled, and stored in the freezer until the assay was commenced. Table 3 details
the specifications of the HPLC instrument and column used for both the separation and
analytical runs.
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Table 3. The HPLC instruments used for the separation and the
analytical runs of the peptides along with the specifications of
the columns.

Preparative
HPLC

Preparative
Column

Analytical
HPLC

Analytical
Column

Waters 600S Controller
Waters 616 Pump
Waters 484 Tunable Abs. Detector
Fisher Recordall Series 5000
Phenomenex Jupiter
10 µm
C18
250 x 21.2 mm
300 Å
Waters automated Gradient Controller
Waters 515 HPLC pump
Waters 490E Programmable Multi-λ Detector
Shimadzu CR501 Chromatopac
Phenomenex Jupiter
5 µm
C18
250 x 4.6 mm
300 Å

Note: The separation HPLC was used to purify the desired
peptides from the unwanted side products. The analytical
HPLC was used to ensure that there were no contaminants
once the separation was completed.
3.4 Dye Leakage Assay
The dye leakage assay was adapted from a similar assay conducted at the University of
Michigan. Frequent trials were conducted in order to determine the proper concentrations
of all the necessary components as well as proper calibration and parameters of the
instruments.
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The vesicles were prepared by taking 5 mg of a lipid, either 1-palmitoyl-2-oleoyl-snglycero-3-phosphocholine (POPC) or 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol
(POPG), and dissolving it in 2 mL of chloroform. The chloroform was evaporated by a
gaseous nitrogen flow to create a thin film of lipid on the side of a test tube, which was then
placed in a vacuum dessicator overnight. 500 L of a 30 mM carboxyfluorescein dye in pH
7.5 sodium phosphate buffer solution was added to the previously prepared dried lipid.
This solution was vortexed to thoroughly mix the components and then subsequently frozen
using liquid nitrogen and thawed five times consecutively. This solution was then extruded
21 times using a mini-extruder from Avanti Polar Lipids, Inc. Following extrusion, the
vesicles last only six hours before they start to degrade and become useless for the dye
leakage assay. The lipid-vesicle solution was placed on a Sephadex G50 gel exclusion column
and the first colored fragment, the separated dye containing vesicles, was collected.
To make the peptide solution, a purified peptide was dissolved in 0.25 times the same
amount of dimethyl sulfoxide (DMSO). This peptide solution was sonicated for one minute.
This is the peptide solution that the aliquots mentioned later were taken from. Other
solutions of interest included the detergent, Triton X, which was used as the control for
100% leakage.
The isolated vesicles containing the carboxyfluorescein were analyzed using scanning
FT-vis to determine that the wavelength of maximum absorption was 489 nm. The
wavelength of maximum absorption is important because this is where the vesicles absorb
the maximum amount of energy. Using a scanning spectrofluorometer, the wavelength of
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maximum absorbance was set as the excitation wavelength and the emission wavelength
was determined to be 513 nm. Using the wavelength of maximum absorbance for excitation
allows the emission, which is what will be measured during the assay, to yield the maximum
reading possible. In order to obtain fluorescence in the range of the instrument, it was
necessary to discover the correct ratio of buffer, vesicles, and peptide. After several ratio
problems, the correct concentration of vesicles and lipid to use during the assay, which
were also is in the range of the instrument, were discovered. An aliquot of 40.0 µL of the
vesicle solution was added to 3.00 mL of the aforementioned sodium phosphate buffer in a
clear, plastic, 4 mL cuvette. To this cuvette, the peptide solution was added in consecutively
increasing amounts: 2.5, 5.0, 10.0, 15.0, 20.0, 25.0, 35.0, 50.0, 75.0, and 100 µL.
Immediately upon adding the peptide solution, the cuvette was inverted and inserted into
the spectrofluorometer, and a time-course fluorescence spectrum was taken over 300
seconds. During the assay, the peptide disrupts the membrane, which causes the
carboxyfluorescein to leak out. As the concentration of the IAPP increases, the membrane
becomes more permeabilized and more carboxyfluorescein dye will leak out, causing
greater fluorescence. The blank used was 2.5 µL pure DMSO in place of the peptide,
whereas the positive control (100% leakage) was 40.0 µL Triton X (10% v/v in buffer). The
spectra were saved and compiled in Microsoft Excel.
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Results and Discussion
4.1 Insulin Synthesis: LKH-1 and LKH-2
The first portion of the research that was addressed was an attempt to synthesize LKH2, Alanyl-Leucyl-N Methyl Tyrosyl-Leucyl-Valine. This synthesis was attempted three times
with the same result each time. The first attempt of synthesis utilized a bottle of n-methyl
tyrosine that was of an unknown age, but presumably at least several years old. The peptide
synthesis was completed, and cleavage commenced with no visible problems. During
cleavage of the peptide, there was a characteristic color change due to the presence of
scavengers. However, when the cold diethyl ether was added to precipitate the peptide, no
precipitate was formed. Because unnatural amino acids are relatively unstable, it was
thought that the N-methyl tyrosine was degraded to such an extent that the synthesis
failed. More of the unnatural amino acid was ordered, and the synthesis was repeated. The
second time the synthesis was carried out, there was absolutely no difference in the results
when compared to the first result.
When the synthesis was begun a third time, it was observed that the N-methyl tyrosine
had undergone some sort of phase change, reaction, or degradation inside its container.
The container had been stored in a freezer at -17° C in an amber-tinted vial. When first
received, the unnatural amino acid was the typical white powder, similar to other amino
acids, and was used immediately. Prior to the third synthesis, its appearance had changed
to an amber-colored liquid with such an extremely high viscosity to appear almost as a
sticky solid. There still has been no conclusive determination as to why that happened. No
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other reports of that occurrence have been discovered in any literature source. The vial
was sealed airtight and was used only once during the second synthesis, so contamination
from an outside source was not a likely culprit. The most likely possibility was that the
amino acid was left unrefrigerated for too long and had undergone some sort of thermal
degradation. Regardless of the cause, the amino acid was transferred to a lyophilization
flask, dissolved in dH2O, frozen, and lyophilized for several days in the hope of removing any
possible water contamination and recollecting a crystalline powder form of the amino acid.
Most of the amino remained in a solid amber color, although some did return to a
crystalline powder. This powder was used to synthesize the LKH-2 peptide a third and final
time. Once again the synthesis occurred without apparent problems, but following
cleavage, no peptide precipitated out of solution following addition of diethyl ether. Since
the N-methyl tyrosine is expensive and failure had occurred three times already, no further
attempts were made. Other unnatural aromatic amino acids that can replace the tyrosine in
the ALYLV segment are being considered for future work.
The most probable reason that LKH-2 was unable to be synthesized was the use of Fmoc
methods during solid phase peptide synthesis. It is well known that Boc methods are
necessary when synthesizing peptides with unnatural amino acids that are base sensitive.38
Since N-methyl tyrosine does have a phenol R-group, it is possible that the Fmoc method
prohibits chain growth of this particular amino acid and that the Boc method is required.
The addition of the methyl group to the tyrosine could theoretically add steric hindrance to
the α-amine by the methyl group, which is more likely to interfere with the coupling, or
perhaps the deprotectant. This would stop growth of the peptide chain by prohibiting either
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the deprotection or coupling step to work properly. The methyl group also makes the amino
acid more basic, which makes the Fmoc method more attractive when synthesizing peptides
with this amino acid. Since Boc deprotects using acid and Fmoc deprotects using base, the
acid deprotection step might be necessary to avoid interaction with the methyl tyrosine.
This would explain the lack of precipitation following cleavage due to the shortness of the
peptide segment synthesized, while also explaining the physical changes seen during
cleavage. Unfortunately, the hypothesis is untestable due to the necessity of using
hydrofluoric acid in the Boc method, and the current unavailability of this dangerous
compound in the laboratory.
A second, although less likely, possibility might be that that the amino acid was simply
degraded prior to use during each synthesis. While with the final synthesis this can
definitely be assumed to have occurred, this is probably not the case due to the use of two
separate samples, one of which was used immediately upon reception. The more likely
possibility is that the methyl group is working as a site-directing functional group prohibiting
a basic deprotection and further peptide synthesis, or steric hindrance of the methyl group
resulting in reduced coupling.
LKH-1, ALYLV, was synthesized following the failure to synthesize LKH-2 to determine if
the method would work for the naturally occurring chain as well as ensure that the
instruments were working properly. LKH-1 was synthesized normally with no complications.
This showed that the instruments worked normally and that the methods were used
properly as well. The LKH-1 was stored and is currently awaiting testing.
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4.2 hIAPP and rIAPP 10-19
Synthesis of hIAPP and rIAPP 10-19 occurred normally; however, the percent yields
were significantly lower than expected using Fmoc methods. The 1st synthesis of hIAPP 1019 resulted in a 10.8% yield after purification while the 2nd synthesis of hIAPP yielded 17.6%.
The reasons for this poor percent yield are not fully understood. Other research has shown
that amyloid segments tend to form β-sheets during synthesis, stop propagation, and
drastically lower the percent yield of the desired compound.38 Suggestions for improved
yield are to switch from O-benzotriazole-N,N,N’,N’-tetramethyluronium
hexafluorophosphate (HBTU) to O-(7-azabenzotriazol-1-yl)-1,1,3-,3-tetramethyluronium
hexafluorophosphate (HATU). Studies have shown that HATU, while more expensive, is
much more efficient for synthesizing normally difficult-to-synthesize amyloidogenic peptide
segments.39
The second goal of the research was to determine the effect that the IAPP 10-19
segment had on membrane permeability. Full length hIAPP, while a potent compound, is
long and difficult to synthesize. Previous research has shown that the 20-29 fragment is
weaker, but does cause membrane permeabilization.40 However, this fragment does not
contain the insulin-binding fragment so is not useful for these studies. Research in Dr.
Ramamoorthy’s lab at University of Michigan has determined that hIAPP 1-19 has similar
activity to the full length peptide (unpublished results). This peptide contains the insulin
binding fragment but is also long and difficult to synthesize. Therefore, a primary goal of
this work was to determine if the smaller and simpler hIAPP 10-19 sequence also has
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membrane permeabilizing ability. The hIAPP 10-19 was run twice in the fluorescence assay
developed, once using POPC as the lipid vesicle and once using POPG. Measuring the
interaction of the peptide with the different membranes of the two lipids allows the
permeability of the membrane to be established on a more general basis than just one for
one specific type of lipid. Rustenbeck et al. have run studies on the concentration of
glucose-stimulated pancreatic β-cells.41 Phosphatidic acid (PA) and phosphatidylinositolis
are the main lipid components, with 1,2-diacylglycerol and many others playing minor
roles.41 The two main lipids (PA and phosphatidylinositolis) increase in concentration (3.1
vs. 4.7 mol% and 8.6 vs. 11.8 mol%, respectively) when glucose levels become elevated.41
POPC and POPG were chosen because they are more widely used in liposome model
membrane systems, but other lipids will be tested in the future. Figures 8 and 9 both show
the effect that increasing hIAPP 10-19 concentrations had on POPC and POPG, respectively.
Percent leakage is calculated by the formula:

Where control is vesicles and DMSO only.

35

Figure 8: Percent leakage of carboxyfluorescein dye in POPC over time. The lipid membrane is
disrupted by increasing hIAPP 10-19 concentration, which affects the permeability of the
membrane. The rate of permeability change does not change substantially based on
concentration of peptide although overall permeability is proportional.
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Figure 9: Percent leakage of carboxyfluorescein dye in POPG over time. The lipid membrane is
disrupted by increasing hIAPP 10-19 concentration, which affects the permeability of the
membrane. The rate of permeability change does not change substantially based on
concentration of peptide although overall permeability is proportional.
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The Titan X (detergent) data were not shown in the graphs above, but in both cases
gave 100% dye leakage. Detergent data are shown in Figure 12. The hIAPP 10-19 clearly
increases the permeability of the membrane as its concentration increases. This would
confirm the hypothesis that the hIAPP 10-19 segment permeabilizes membranes, as does
the full-length chain, the truncated 8-37 chain, and the 20-29 chain. However, the extent of
permeabilization is different. For the most part, a direct comparison of the results for the
various peptides cannot be made at this point, due to differences in the assays used, but
the percent leakage at the highest concentration tested is certainly much greater for our
sequence than was observed for the hIAPP 20-29 segment, which gave only 0.1 – 0.15 %
leakage at 25 – 50 µM peptide concentration.40 The percent leakage is lower, however, than
what is observed for the full length and 1-19 segments. Further studies are underway to
clarify this in the same assay. The differences between the aliquots are roughly equally
spaced between both of the lipid membranes, even though the overall permeability is not
the same. From Figures 8 and 9, the percent leakage between POPG and POPC by hIAPP 1019 showed no significance difference between the two lipids.
If the data are graphed by intensity of fluorescence instead of by percent leakage, it is
observed that the POPC membrane has an overall lower susceptibility to the peptide than
the POPG based on results from the dye leakage assay. Not only is the overall permeability
greater in POPG, but more importantly, the rate at which the membrane becomes disrupted
is slightly increased as well. This is unexpected given that the percent leakage is the same. It
shows that the Triton X also has a greater effect on POPG, so maybe these vesicles are more
susceptible to permeabilization overall. It would be interesting to note any structural
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similarities between POPG and the β-cells that hIAPP is known to destroy (i.e., the
membrane lipid composition of the β-cell). The increased permeability of the vesicles is an
indicator of membrane destruction. Figures 10 and 11 show the fluorescence graphed as a
function of intensity as opposed to percent leakage.

Figure 10: Overall fluorescence intensity of carboxyfluorescein dye leakage through POPC
over time. The lipid membrane is disrupted by increasing hIAPP 10-19 concentration, which
affects the permeability of the membrane. The rate of permeability does not change
substantially based on concentration of peptide although overall permeability is
proportional.
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Figure 11: Overall fluorescence intensity of carboxyfluorescein dye leakage through POPG
over time. The lipid membrane is disrupted by increasing hIAPP 10-19 concentration, which
affects the permeability of the membrane. The rate of permeability does not change
substantially based on concentration of peptide although overall permeability is
proportional.
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Figure 12: Overall intensity of Triton-X detergent on POPG and POPC. There definitely is a
difference in membrane permeability based on the membrane used. This accounts for the
intensity changes while keeping the percent leakage constant regardless of the lipid membrane
used.
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Summary
An unnatural amino acid was substituted in place of tyrosine inside a short insulin 14-18
segment and synthesis was attempted. The synthesis failed due to problems in the
methodology with the Fmoc protection group that requires a basic solvent for deprotection,
which might interact with the N-methyl tyrosine used. Steric hindrance may also have
interfered with coupling. A suggested improvement would be to find an unnatural aromatic
amino acid derivative of tyrosine which contains no functional groups that might interact with
the chemical deprotectant, or utilize the Boc method for this particular synthesis. The original
insulin 14-18 segment was also synthesized. hIAPP and rIAPP 10-19 were both synthesized with
relatively low yields. Switching from HBTU to HATU could theoretically boost yields, as percent
yields as high as 97% have been reported with this coupling agent for amyloidogenic peptide
segments. A dye leakage assay based on fluorescence of carboxyfluorescein was adapted
specifically for use at Eastern Michigan University and run on the hIAPP 10-19 segment using
both POPC and POPG lipids. The results showed that peptide concentration and membrane
permeability were directly related. The results also showed that the hIAPP segment interacted
slightly differently with the two types of lipid. This allows the pursuit of the synthesis of
possible peptide inhibitors, knowing that hIAPP 10-19, which is shorter and easier to synthesize
than full length and hIAPP 1-19, can be used in the assay to induce membrane permeabilization.
This effect can be compared in the presence and absence of inhibitors to test their potency.

42

Future Work
Since insulin 14-18 was synthesized successfully whereas the N-methyl-tyrosine analog
synthesis failed, the next step should be to synthesize successfully the ALYLV segment with
another aromatic amino acid in place of the tyrosine. Naturally occurring phenylalanine would
be a good choice to test next due to its availability as well as its known compatibility with Fmoc
methods. Following that, synthesis of another chain with another aromatic unnatural amino
acid in the place of the tyrosine would be the next logical step. The selection of this amino acid
would be important, as it should be one that is not sensitive to the basic conditions of the Fmoc
method. Several amino acids with conformational constraints and polycyclic aromatic systems
are planned to assess differences in π-stacking interactions. Since most new research seems to
imply that the aggregation process itself is the step that is cytotoxic to the β-cell, finding a novel
peptide segment that inhibits IAPP aggregation like insulin does naturally would be a major step
towards treating one of the main known causes of adult onset diabetes mellitus.
Once the dye leakage assay is developed and adapted to the chemicals, instruments,
and compounds available, it is a simple matter of synthesizing the desired peptides and
conducting the assays. The 10-19 segment of hIAPP has been tested in the assay using both
POPC and POPG. The next step would be to test the rIAPP 10-19 on the assay using both the
POPC and POPG lipid vesicles. Following comparison of the human and rat variants of the 10-19
segments, various other segments could be synthesized to determine how chain length affects
membrane permeability (the hIAPP 8-19 segment and 1-19 segment are being synthesized for
comparison). Furthermore, substitutions could be done on the human variant, removing the
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aromatic regions to determine if those also contribute to membrane disruption as well as to
binding to other hormones. As was done with both insulin and IAPP by Gilead et al. to
determine binding sites, sequential decamer peptide chains through IAPP could be synthesized,
and their effects on membrane permeability could be studied to determine exactly which
section disrupts membranes the most. Knowing this, it could then be possible to insert a variety
of amino acids into that section and perhaps lower IAPP’s ability to destroy the pancreatic βcells, which is the main cause of adult onset diabetes mellitus.
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